Costs and Effectiveness of Ximelagatran for Stroke Prophylaxis in Chronic Atrial Fibrillation | Zendy

Cara O’Brien | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Costs and Effectiveness of Ximelagatran for Stroke Prophylaxis in Chronic Atrial Fibrillation

Author(s) -

Cara O’Brien

Publication year - 2005

Publication title -

jama

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 4.688

H-Index - 680

eISSN - 1538-3598

pISSN - 0098-7484

DOI - 10.1001/jama.293.6.699

Subject(s) - medicine , ximelagatran , warfarin , atrial fibrillation , stroke (engine) , aspirin , quality adjusted life year , direct thrombin inhibitor , cost effectiveness , cardiology , dabigatran , mechanical engineering , risk analysis (engineering) , engineering

Recent trials have found that ximelagatran and warfarin are equally effective in stroke prevention for patients with atrial fibrillation. Because ximelagatran can be taken in a fixed, oral dose without international normalized ratio monitoring and may have a lower risk of hemorrhage, it might improve quality-adjusted survival compared with dose-adjusted warfarin.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research